AstraZeneca: Very encouraging preliminary phase II data for AZD9291 in lung cancer

NEUTRAL, Fair Value  4830p (+19%)
News published on August Monday 24, 2015
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities